JPH05508553A - マウスモノクローナル抗体 - Google Patents
マウスモノクローナル抗体Info
- Publication number
- JPH05508553A JPH05508553A JP91518456A JP51845691A JPH05508553A JP H05508553 A JPH05508553 A JP H05508553A JP 91518456 A JP91518456 A JP 91518456A JP 51845691 A JP51845691 A JP 51845691A JP H05508553 A JPH05508553 A JP H05508553A
- Authority
- JP
- Japan
- Prior art keywords
- monoclonal antibody
- antibodies
- cancer
- tumor
- monoclonal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (21)
- 1.細胞表面エピトープに特異的なモノクローナル抗体を産生するハイプリドー マであって、上記エビトープが正常霊長類組織、悪性ヒト培養細胞系及びヒト腫 瘍で発現されることを特徴とする、ハイブリドーマ。
- 2.細胞表面エビトープに特異的なモノクローナル抗体であって、 上記エビトープが正常霊長類組織、悪性ヒト培養細胞系及びヒト腫瘍で発現され 、上記モノクローナル抗体のクラスがIgG又はIgMであることを特徴とする 、モノクローナル抗体。
- 3.悪性ヒト培養細胞系がA431、MCF−7、HTB20及びHTB33か らなる群より選択される、請求項1に記載のハイプリドーマ。
- 4.悪性ヒト培養細胞系がA431、MCF−7、HTB20及びHTB33か らなる群より選択される、請求項2に記載のモノクローナル抗体。
- 5.正常霊長類組織が食道、膀胱又は胃に由来する、請求項1に記載のハイブリ ドーマ。
- 6.正常霊長類組織が食道、膀胱又は胃に由来する、請求項2に記載のモノクロ ーナル抗体。
- 7.ヒト腫瘍が結腸、胃又は卵巣癌腫に由来する、請求項1に記載のハイプリド ーマ。
- 8.腫瘍が結腸、胃又は卵巣癌腫に由来する、請求項2に記載のモノクローナル 抗体。
- 9.受託番号がATCCHB10572である、ハイブリドーマ細胞系。
- 10.受託番号がATCCHB10673である、ハイブリドーマ細胞系。
- 11.受託番号がATCCHB10669である、ハイプリドーマ細胞系。
- 12.そのモノクローナル抗体がB1である、請求項9に記載のハイブリドーマ により産生されるモノクローナル抗体。
- 13.そのモノクローナル抗体がB3である、請求項10に記載のハイブリドー マにより産生されるモノクローナル抗体。
- 14.そのモノクローナル抗体がB5である、請求項11に記載のハイプリドー マにより産生されるモノクローナル抗体。
- 15.請求項2に記載のモノクローナル抗体の複合体の癌の治療のための使用。
- 16.モノクローナル抗体を毒素、放射性核種又は化学療法剤と結合させた、請 求項15に記載の使用。
- 17.毒素がシュードモナスエクソトキシンである、請求項15に記載の使用。
- 18.化学療法剤がビンプラスチン又はダウノマイシンである、請求項15に記 載の使用。
- 19.血液サンプルを患者から採取し、癌流出抗原と反応して抗原−抗体複合体 を形成させるために十分な量の請求項2に記載のモノクローナル抗体を上記サン プルに加え、そして 上記複合体の存在又は不存在を調べることによって癌がその患者に存在するか否 かについて検出することを特徴とする癌の診断のための請求項2に記載されたモ ノクローナル抗体の使用。
- 20.組織又は液体サンプルを患者から取り出し、上記サンプルに請求項2に記 載のモノクローナル抗体を加え、そして 上記サンプル中における抗体の存在を視覚化することを特徴とする、癌の診断に 関する請求項2に記載のモノクローナル抗体の用途。
- 21.薬学上許容されるキャリアと共に請求項2に記載のモノクローナル抗体を 腫瘍増殖を阻害する上で十分な濃度で含んでなる、医薬組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US596,289 | 1990-10-12 | ||
US07/596,289 US5242813A (en) | 1990-10-12 | 1990-10-12 | Mouse monoclonal antibodies specific for normal primate tissue, malignant human cultural cell lines human tumors |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH05508553A true JPH05508553A (ja) | 1993-12-02 |
JP2651046B2 JP2651046B2 (ja) | 1997-09-10 |
Family
ID=24386733
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP3518456A Expired - Fee Related JP2651046B2 (ja) | 1990-10-12 | 1991-10-09 | マウスモノクローナル抗体 |
Country Status (11)
Country | Link |
---|---|
US (2) | US5242813A (ja) |
EP (1) | EP0552296B1 (ja) |
JP (1) | JP2651046B2 (ja) |
AT (1) | ATE161582T1 (ja) |
AU (1) | AU650302B2 (ja) |
CA (1) | CA2093667C (ja) |
DE (1) | DE69128543T2 (ja) |
DK (1) | DK0552296T3 (ja) |
ES (1) | ES2113891T3 (ja) |
GR (1) | GR3026219T3 (ja) |
WO (1) | WO1992007271A1 (ja) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5242813A (en) * | 1990-10-12 | 1993-09-07 | The United States Of America As Represented By The Department Of Health And Human Services | Mouse monoclonal antibodies specific for normal primate tissue, malignant human cultural cell lines human tumors |
US5889157A (en) * | 1990-10-12 | 1999-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Humanized B3 antibody fragments, fusion proteins, and uses thereof |
US5981726A (en) * | 1990-10-12 | 1999-11-09 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric and mutationally stabilized tumor-specific B1, B3 and B5 antibody fragments; immunotoxic fusion proteins; and uses thereof |
US5608039A (en) * | 1990-10-12 | 1997-03-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Single chain B3 antibody fusion proteins and their uses |
ES2121792T3 (es) * | 1990-10-12 | 1998-12-16 | Us Health | Anticuerpo monoclonal. |
US5877289A (en) * | 1992-03-05 | 1999-03-02 | The Scripps Research Institute | Tissue factor compositions and ligands for the specific coagulation of vasculature |
US6093399A (en) * | 1992-03-05 | 2000-07-25 | Board Of Regents, The University Of Texas System | Methods and compositions for the specific coagulation of vasculature |
US6749853B1 (en) * | 1992-03-05 | 2004-06-15 | Board Of Regents, The University Of Texas System | Combined methods and compositions for coagulation and tumor treatment |
US6036955A (en) * | 1992-03-05 | 2000-03-14 | The Scripps Research Institute | Kits and methods for the specific coagulation of vasculature |
US6004555A (en) * | 1992-03-05 | 1999-12-21 | Board Of Regents, The University Of Texas System | Methods for the specific coagulation of vasculature |
US5489525A (en) * | 1992-10-08 | 1996-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Monoclonal antibodies to prostate cells |
US5597569A (en) * | 1993-10-25 | 1997-01-28 | Bristol-Myers Squibb Company | Bryodin 2 a ribosome-inactivating protein isolated from the plant Bryonia dioica |
DE19547324C2 (de) * | 1995-12-19 | 1997-10-16 | Behringwerke Ag | Humanes Muzin (MUC8) |
JP2002506832A (ja) * | 1998-03-20 | 2002-03-05 | ジェンザイム・コーポレーション | 抗癌免疫応答を誘導する方法 |
WO1999059578A1 (en) | 1998-05-19 | 1999-11-25 | Research Development Foundation | Triterpene compositions and methods for use thereof |
AU7701100A (en) * | 1999-09-03 | 2001-04-10 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer |
WO2002046765A2 (en) * | 2000-11-08 | 2002-06-13 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer |
US20060148732A1 (en) * | 2000-11-17 | 2006-07-06 | Gutterman Jordan U | Inhibition of NF-kappaB by triterpene compositions |
WO2003035688A2 (en) * | 2001-10-26 | 2003-05-01 | Novartis Pharma Gmbh | Targeted thrombosis by tissue factor polypeptides |
DK2283868T3 (en) | 2002-07-15 | 2016-04-25 | Univ Texas | PEPTIDES BINDING TO PHOSPHATIDYLETHANOLAMINE AND ITS USE IN TREATING VIRUS INFECTIONS AND CANCER |
MX2010005104A (es) | 2007-11-09 | 2010-08-04 | Peregrine Pharmaceuticals Inc | Composiciones de anticuerpo anti-factor de crecimiento endotelial vascular y metodos. |
KR101133243B1 (ko) | 2009-10-29 | 2012-04-06 | 국립암센터 | 암의 진단 및 치료를 위한 eIF3m의 용도 |
EA201291181A1 (ru) | 2010-05-06 | 2013-05-30 | Новартис Аг | Композиции и способы применения терапевтических поливалентных антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6) |
ES2949159T3 (es) | 2010-05-06 | 2023-09-26 | Novartis Ag | Composiciones y métodos de uso para anticuerpos terapéuticos de proteína 6 relacionada con lipoproteínas de baja densidad (LRP6) |
EP3290442A1 (en) | 2011-11-04 | 2018-03-07 | Novartis AG | Low density lipoprotein-related protein 6 (lrp6) half-life extender constructs |
UY36449A (es) | 2014-12-19 | 2016-07-29 | Novartis Ag | Composiciones y métodos para anticuerpos dirigidos a bmp6 |
AU2017283787B2 (en) | 2016-06-15 | 2020-09-17 | Novartis Ag | Methods for treating disease using inhibitors of bone morphogenetic protein 6 (BMP6) |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0044167A3 (en) * | 1980-07-14 | 1982-04-21 | The Regents Of The University Of California | Antibody targeted cytotoxic agent |
US4713352A (en) * | 1981-08-31 | 1987-12-15 | Sloan-Kettering Institute For Cancer Reseach | Monoclonal antibody panel for early diagnosis and therapy of renal carcinoma |
JPS5843926A (ja) * | 1981-09-08 | 1983-03-14 | Suntory Ltd | 選択性制癌剤 |
CA1215331A (en) * | 1983-03-04 | 1986-12-16 | Tsann M. Chu | Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy |
US4699783A (en) * | 1983-03-11 | 1987-10-13 | Terman David S | Products and methods for treatment of cancer |
ATE74382T1 (de) * | 1984-12-05 | 1992-04-15 | Salk Inst For Biological Studi | Monoklonaler antikoerper, spezifisch fuer brustkrebszelloberflaechenantigen. |
IL94872A (en) * | 1989-06-30 | 1995-03-30 | Oncogen | Monoclonal or chimeric antibodies that react with human carcinoma, recombinant proteins that contain their anti-binding site, pharmaceutical preparations and kits that contain the |
US5242813A (en) * | 1990-10-12 | 1993-09-07 | The United States Of America As Represented By The Department Of Health And Human Services | Mouse monoclonal antibodies specific for normal primate tissue, malignant human cultural cell lines human tumors |
ES2121792T3 (es) * | 1990-10-12 | 1998-12-16 | Us Health | Anticuerpo monoclonal. |
-
1990
- 1990-10-12 US US07/596,289 patent/US5242813A/en not_active Expired - Lifetime
-
1991
- 1991-10-09 ES ES91920282T patent/ES2113891T3/es not_active Expired - Lifetime
- 1991-10-09 AT AT91920282T patent/ATE161582T1/de not_active IP Right Cessation
- 1991-10-09 JP JP3518456A patent/JP2651046B2/ja not_active Expired - Fee Related
- 1991-10-09 DE DE69128543T patent/DE69128543T2/de not_active Expired - Fee Related
- 1991-10-09 DK DK91920282.0T patent/DK0552296T3/da active
- 1991-10-09 CA CA002093667A patent/CA2093667C/en not_active Expired - Fee Related
- 1991-10-09 AU AU89050/91A patent/AU650302B2/en not_active Ceased
- 1991-10-09 EP EP91920282A patent/EP0552296B1/en not_active Expired - Lifetime
- 1991-10-09 WO PCT/US1991/007226 patent/WO1992007271A1/en active IP Right Grant
-
1994
- 1994-12-22 US US08/363,203 patent/US5612032A/en not_active Expired - Lifetime
-
1998
- 1998-02-25 GR GR980400398T patent/GR3026219T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
DK0552296T3 (da) | 1998-04-27 |
DE69128543T2 (de) | 1998-07-16 |
CA2093667A1 (en) | 1992-04-13 |
EP0552296A4 (en) | 1994-02-16 |
ATE161582T1 (de) | 1998-01-15 |
AU650302B2 (en) | 1994-06-16 |
ES2113891T3 (es) | 1998-05-16 |
AU8905091A (en) | 1992-05-20 |
GR3026219T3 (en) | 1998-05-29 |
DE69128543D1 (de) | 1998-02-05 |
WO1992007271A1 (en) | 1992-04-30 |
US5612032A (en) | 1997-03-18 |
US5242813A (en) | 1993-09-07 |
JP2651046B2 (ja) | 1997-09-10 |
EP0552296A1 (en) | 1993-07-28 |
CA2093667C (en) | 2000-02-15 |
EP0552296B1 (en) | 1997-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH05508553A (ja) | マウスモノクローナル抗体 | |
US5489525A (en) | Monoclonal antibodies to prostate cells | |
RU2266298C2 (ru) | Антитела к антигену эпителиальных опухолей желудочно-кишечного тракта человека, родственному альфа 6 бета 4 интегрину | |
JP5192537B2 (ja) | 癌抗原tmeff2に対する抗体及びそれらの使用 | |
JP6326137B2 (ja) | 抗her2抗体及びその結合体 | |
JP2756329B2 (ja) | 癌の診断、治療のための免疫結合体 | |
US5817313A (en) | Monoclonal antibodies and conjugates thereof useful for the treatment of cancer | |
JP3492373B2 (ja) | モノクローナル抗体 | |
JP4854912B2 (ja) | 癌に対する抗体 | |
JPH05504330A (ja) | ヒトのがん腫と反応する新しい抗体 | |
CN108136015A (zh) | 抗dll3抗体药物缀合物以及使用方法 | |
JP2007525410A (ja) | 膵臓癌に関連する抗原、それらに対する抗体、及び診断方法及び処置方法 | |
CN104059150A (zh) | 结合epha2的抗体及其使用方法 | |
US20070042447A1 (en) | Use of anti-ferritin monoclonal antibodies in the treatment of some cancers (divisional) | |
US5846535A (en) | Methods for reducing tumor cell growth by using antibodies with broad tumor reactivity and limited normal tissue reactivity | |
AU2004289821B2 (en) | Adenocarcinoma specific antibody SAM-6, and uses thereof | |
US20030176661A1 (en) | Novel antibody with specificity for colon cancer | |
JP3268147B2 (ja) | モノクローナル抗体 | |
CA2421070A1 (en) | The identification and development of specific monoclonal antibodies to squamous cell carcinoma | |
CN113993897A (zh) | 抗tie2抗体及其用途 | |
AU650080B2 (en) | Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents | |
US20100119514A1 (en) | Antibodies Against Cancer | |
JPS60231622A (ja) | ムチン性卵巣癌細胞モノクロ−ナル抗体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090516 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100516 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110516 Year of fee payment: 14 |
|
LAPS | Cancellation because of no payment of annual fees |